# Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Source: https://onco.cc/trials/nct05163041/  
OnCo record `nct05163041` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nivolumab in advanced solid tumours, run by BicycleTx Limited, active and no longer recruiting.

## Summary

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression is a phase 1/2 interventional study registered as NCT05163041 by BicycleTx Limited, with 200 participants enrolled, started 2021-11-02 and due to reach its primary completion in 2026-08. Interventions recorded: BT7480 and Nivolumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05163041
- Phase: 1/2
- Setting: Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies
- Sponsor: BicycleTx Limited
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05163041: https://clinicaltrials.gov/study/NCT05163041

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05163041.json